Condition: Human Immunodeficiency Virus · Sponsor: U.S. Army Medical Research and Development Command
This is a Phase I, randomized, double-blind, placebo-controlled clinical study to define the safety and immunogenicity resulting from a rapid dose-escalating vaccination schedule as compared to that of a co-administered, dose-consistent vaccination schedule. Participants randomized to receive vaccines will get either dose-consistent injections of CH505 TF chTrimer+ALFQ co-administered with Ad26.Mos4.HIV or rapid, dose-escalating injections of CH505 TF chTrimer+ALFQ with an Ad26.Mos4.HIV prime, followed by dose-consistent injection of CH505 TF chTrimer+ALFQ co-administered with Ad26.Mos4.HIV
This description comes directly from the study's public registry record.
Grace Mirembe, MBChB, MMed · +256 312 330400 · gmirembe@muwrp.org
Hannah Kibuuka, MBChB, MMed, MPH · +256 312 330400 · hkibuuka@muwrp.org
Always discuss trial participation with your own doctor first.
| Makerere University Walter Reed Project (MUWRP) | Kampala, Uganda | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06205056